Epoch Investment Partners Inc. Has $184.45 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Epoch Investment Partners cut its stake in Regeneron Pharmaceuticals by 15.1% in the first quarter, selling 42,610 shares and leaving it with 238,725 shares valued at about $184.45 million.
• Wall Street remains broadly positive on REGN, with a consensus Moderate Buy rating and an average target price of $787.88, though several firms recently adjusted targets slightly higher or lower.
• Regeneron reported a strong quarter, posting $9.47 EPS versus the $8.91 estimate and $3.61 billion in revenue, up 19% year over year; the company also paid a quarterly dividend of $0.94 per share.

Epoch Investment Partners Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 238,725 shares of the biopharmaceutical company's stock after selling 42,610 shares during the period. Regeneron Pharmaceuticals accounts for 1.1% of Epoch Investment Partners Inc.'s holdings, making the stock its 13th biggest holding. Epoch Investment Partners Inc. owned 0.23% of Regeneron Pharmaceuticals worth $184,448,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. WPG Advisers LLC increased its position in Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Kemnay Advisory Services Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Finally, Entrust Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on REGN. Barclays cut their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a report on Thursday, April 30th. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a "buy" rating in a report on Thursday, April 23rd. Leerink Partners reaffirmed a "market perform" rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating for the company in a report on Wednesday, April 8th. Finally, HSBC lowered their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $787.88.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $656.01 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market cap of $69.35 billion, a PE ratio of 15.98, a price-to-earnings-growth ratio of 1.45 and a beta of 0.24. The stock's fifty day simple moving average is $635.78 and its two-hundred day simple moving average is $714.44. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the company posted $8.22 earnings per share. The firm's revenue for the quarter was up 19.0% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals's payout ratio is presently 9.16%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals NASDAQ: REGN Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.